Experience with rufinamide in a pediatric population: A single center's experience

Martina Vendrame, Tobias Loddenkemper, Vasu D. Gooty, Masanori Takeoka, Alexander Rotenberg, Ann M. Bergin, Yaman Z. Eksioglu, Annapurna Poduri, Frank H. Duffy, Mark Libenson, Blaise F. Bourgeois, Sanjeev V. Kothare

Research output: Contribution to journalArticlepeer-review

46 Scopus citations


Rufinamide is a new antiepileptic drug recently approved as adjunctive treatment for generalized seizures in Lennox-Gastaut syndrome. We undertook a retrospective analysis of 77 patients with refractory epilepsy and receiving rufinamide to evaluate the drug's efficacy, tolerability, safety, and dosing schedules. It appeared efficacious in diverse epilepsy syndromes, with the highest responder rate in focal cryptogenic epilepsies (81.1% of patients with >50% response rate), and in diverse seizure types, with the highest responder rate in tonic/atonic and partial seizures (48.6% and 46.7% of patients with >50% response rate, respectively). Rufinamide was well tolerated: only 13% of patients developed side effects necessitating drug withdrawal. These findings suggest that rufinamide may possess good efficacy and tolerability, and that its efficacy may extend to epilepsy syndromes beyond Lennox-Gastaut, including both partial and generalized epilepsy syndromes.

Original languageEnglish (US)
Pages (from-to)155-158
Number of pages4
JournalPediatric Neurology
Issue number3
StatePublished - Sep 2010

Bibliographical note

Funding Information:
This study was funded in part by an Investigator Initiated Grant from Eisai Pharma, Inc ., to S.V.K. and T.L. for analyzng the data.


Dive into the research topics of 'Experience with rufinamide in a pediatric population: A single center's experience'. Together they form a unique fingerprint.

Cite this